Fri, January 27, 2023
Thu, January 26, 2023
Wed, January 25, 2023
Tue, January 24, 2023

Corinne Jenkins Maintained (BTAI) at Hold with Increased Target to $26 on, Jan 26th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-increased-target-to-26-on-jan-26th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Corinne Jenkins of Goldman Sachs, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Increased Target from $16 to $26 on, Jan 26th, 2023.

Corinne has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Corinne's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Corinne


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $73 on, Tuesday, January 3rd, 2023
  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $18 on, Wednesday, November 16th, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022

Publication Contributing Sources